Article (Scientific journals)
Sentinel lymph node mapping with patent blue dye in patients with breast cancer: a retrospective single institution study.
OLIVIER, Fabrice; Courtois, Audrey; Jossa, Veronique et al.
2021In Gland Surgery, 10 (9), p. 2600-2607
Peer Reviewed verified by ORBi
 

Files


Full Text
Olivier Gland surgery.pdf
Author postprint (676.99 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Early breast cancer; axillary lymph nodes dissection (ALND); blue dye; sentinel lymph nodes biopsy (SLNB); Surgery
Abstract :
[en] BACKGROUND: Since the end of the last century, sentinel lymph node biopsy (SLNB) has replaced axillary lymph node dissection (ALND) as standard of care for axillary staging in early breast cancer in patients without any clinical sign of axillary lymph node infiltration. The worldwide most frequently used mapping method consists in the injection of radioactive technetium-99 isotope alone or in combination with blue dye. As a specific infrastructure and dedicated personnel are needed for the use of a radioactive tracer, the CHC in Liege (Belgium) decided to test the use of patent blue dye alone to detect sentinel lymph nodes in a large consecutive cohort of patients and compared the results with radioactive mapping methods and guidelines recommendations. METHODS: Patent blue dye was used in 456 consecutive patients with early breast cancer who underwent conservative breast cancer surgery or radical mastectomy between 1/1/2000 and 31/12/2007 in a community hospital (CHC Liège, Belgium). After SLNB, an ALND was performed in each patient. RESULTS: Sentinel lymph nodes were identified in 444 patients among the 456 patients evaluated by this mapping method during this time period, which represents a detection rate of 97.4%. Infiltrated lymph nodes were detected in 32.7% of patients (149/456) while in the 444 patients with sentinel lymph nodes identified and resected, 137 patients have at last one positive lymph node (30.9%). The false negative rate was 4.9% and the predictive negative value was 97.7% with the blue dye mapping method. CONCLUSIONS: In addition of the simplicity of the method and the large economic advantage, SNLB using blue dye alone showed a quite acceptable performance in our retrospective analysis concerning its ability to find the SLN as well as its reliability to remove the good ones.
Disciplines :
Oncology
Author, co-author :
OLIVIER, Fabrice  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
Courtois, Audrey  ;  Université de Liège - ULiège > Département des sciences cliniques > Chirurgie cardio-vasculaire et thoracique
Jossa, Veronique;  Anatomo-pathology Department, CHC Montlegia, Liege, Belgium
Bruck, Gaelle;  Gynecology Department, CHR Citadelle, Liege, Belgium
Aouachria, Samy;  Medical Direction Department, CHC Montlegia Liege, Belgium
Coibion, Michel  ;  Université de Liège - ULiège ; Gynecology Department, CHC Montlegia, Liege, Belgium
JERUSALEM, Guy   ;  Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
 These authors have contributed equally to this work.
Language :
English
Title :
Sentinel lymph node mapping with patent blue dye in patients with breast cancer: a retrospective single institution study.
Publication date :
September 2021
Journal title :
Gland Surgery
ISSN :
2227-684X
eISSN :
2227-8575
Publisher :
AME Publishing Company, China republic 1949
Volume :
10
Issue :
9
Pages :
2600-2607
Peer reviewed :
Peer Reviewed verified by ORBi
Funding text :
Funding: None
Available on ORBi :
since 15 June 2022

Statistics


Number of views
131 (0 by ULiège)
Number of downloads
89 (0 by ULiège)

Scopus citations®
 
4
Scopus citations®
without self-citations
3
OpenCitations
 
1

Bibliography


Similar publications



Contact ORBi